drugset
Drugs / TQH2722
last change 17 days ago re-read 3 minutes ago

TQH2722

also known as TQH2722 injection

Monoclonal antibody targets IL4R

Developed for
atopic eczema · seasonal allergic rhinitis · chronic rhinosinusitis · sinusitis
Investigated by
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed China (NMPA) — atopic eczema 2026-09-16

“注射用TQB2102及TQH2722注射液的上市申请同日被受理，分别用于既往在复发或转移性疾病阶段未接受过化疗的不可切除或转移性HER2低表达（IHC 1+或IHC 2+/ISH-）成人乳腺癌患者，及治疗外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎（AD）。” cttq.com ↗

Trials 7

today NCT07398859 · Ph 2 NCT06760182 · Ph 2 NCT06552520 · Ph 3 NCT06439381 · Ph 2 NCT06089278 · Ph 2 NCT05970432 · Ph 2 NCT05409326 · Ph 1
20232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05409326 Jun 2022 → Jun 2023 atopic eczema Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 25 trials
Phase 2 NCT07398859 Mar → Nov 2026 expected seasonal allergic rhinitis Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06760182 Mar → Apr 2025 seasonal allergic rhinitis Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Completed No outcome recorded
Phase 2 NCT06439381 Jul 2024 → Jun 2026 overdue chronic rhinosinusitis Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06089278 Dec 2023 → Mar 2025 sinusitis Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 2 NCT05970432 Jun 2023 → Mar 2024 atopic eczema Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Unknown No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT06552520 Oct 2024 → Sep 2025 overdue atopic eczema Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Active not recruiting Met primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as TQH2722 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07398859 ↗
6

NCT06552520 ↗

NCT06089278 ↗

NCT06439381 ↗

NCT05409326 ↗

NCT05970432 ↗

NCT06760182 ↗
Known as TQH2722 injection “TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.” NCT06439381 ↗
Modality Monoclonal antibody “TQH2722 is a fully human monoclonal antibody” NCT05409326 ↗
Route Subcutaneous “TQH2722 was subcutaneously injected” PMID 40221092 ↗ Apr 2025
Target IL4R “TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα)” NCT05409326 ↗